A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.
-
アブストラクト Efforts to combat the global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from adequate diagnostic testing and contract tracing to vaccination for the prevention of coronavirus disease 2019 (COVID-19). In the United States alone, three vaccinations have been authorized for emergency use (EUA) or approved to prevent COVID-19. The Ad26.COV2.S vaccine by Johnson and Johnson (New Brunswick, New Jersey) is the only adenovirus-based vaccine and deemed relatively effective and safe by the US Food and Drug Administration (FDA) following its clinical trial. Since its introduction, the US FDA has placed a warning on the vaccine adverse event reporting system (VAERS) after more than 100 cases of Guillain-Barre Syndrome (GBS) were reported. Herein, we outline the hospital course of a generally healthy 49-year-old female who experienced an axonal form of GBS nine days after receiving the Ad26.COV2.S vaccine. ジャーナル名 Cureus Pubmed追加日 2021/10/28 投稿者 Morehouse, Zachary P; Paulus, Amanda; Jasti, Sri A; Bing, Xue 組織名 Family and Community Medicine, Michigan State University College of Osteopathic;Medicine, East Lansing, USA.;Research and Development, Omni International Inc., Kennesaw, USA.;Internal Medicine, Michigan State University College of Osteopathic Medicine,;East Lansing, USA.;Internal Medicine, St. Joseph Mercy Ann Arbor Hospital, Ypsilanti, USA.;Pulmonary and Critical Care Medicine, St. Joseph Mercy Ann Arbor Hospital,;Ypsilanti, USA. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/34703690/ -
お問合わせ
検索
メルマガ登録
